HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsueh, E. C. Articles by Giuliano, A. E. Search for Related Content PubMed PubMed Citation Articles by Hsueh, E. C. Articles by Giuliano, A. E.

CA: A Cancer Journal for Clinicians, Vol 50, Issue 5 279-291, Copyright © 2000 by American Cancer Society

ARTICLES

Intraoperative lymphatic mapping and sentinel lymph node dissection in breast cancer

E. C. Hsueh, N. Hansen and A. E. Giuliano
John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA.

Because the tumor status of the regional lymph nodes is the most important prognostic factor in patients with early-stage breast cancer, accurate histopathologic assessment of these nodes is essential for optimal management, including the selection of candidates for adjuvant systemic therapies. Intraoperative lymphatic mapping using a vital blue dye, with or without a radiocolloid, can identify the first axillary node to receive lymphatic drainage from a primary breast carcinoma. Focused histopathologic assessment of this sentinel node can be used to determine the tumor status of the entire axillary basin. The minimal morbidity and high accuracy of sentinel lymph node dissection (SLND) in breast cancer have been validated by multiple independent investigators, and the data suggest that this surgical technique may eventually replace complete lymph node dissection as the preferred axillary procedure for the management of early-stage disease. In experienced hands, SLND can be successfully performed in more than 90% of eligible breast cancer patients; the tumor status of the sentinel node accurately predicts the status of all axillary nodes in more than 95% of cases. This article reviews the current status, controversies, and future directions of SLND as a staging technique for patients with primary breast carcinoma.

This article has been cited by other articles:

				S. L. Chen, D. M. Iddings, R. P. Scheri, and A. J. Bilchik Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications CA Cancer J Clin, September 1, 2006; 56(5): 292 - 309. [Abstract] [Full Text] [PDF]

				K. I. Bland Utilization of Sentinel Lymph Node Mapping to Determine Pathologic Outcomes for Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 217 - 219. [Full Text] [PDF]

				V. Stearns, C. A. Ewing, R. Slack, M. F. Penannen, D. F. Hayes, and T. N. Tsangaris Sentinel Lymphadenectomy After Neoadjuvant Chemotherapy for Breast Cancer May Reliably Represent the Axilla Except for Inflammatory Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 235 - 242. [Abstract] [Full Text] [PDF]

				A. R. Miller, V. E. Thomason, I-T. Yeh, A. Alrahwan, F. E. Sharkey, J. Stauffer, P. M. Otto, C. McKay, M. S. Kahlenberg, W. T. Phillips, et al. Analysis of Sentinel Lymph Node Mapping With Immediate Pathologic Review in Patients Receiving Preoperative Chemotherapy for Breast Carcinoma Ann. Surg. Oncol., April 1, 2002; 9(3): 243 - 247. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, and H.-J. Senn Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer J. Clin. Oncol., September 15, 2001; 19(18): 3817 - 3827. [Full Text] [PDF]